North American Vaccine Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine

NVX 1.245

+2.9%

12:24 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Paul Lee who wrote (372)	6/11/1998 10:46:00 AM
From: Don W Stone	Read Replies (1) of 507

This is great news. 1. We are now talking about a big European market. 2. Chiron/Behring , NVX's marketing partner, dominates their market in Germany and Austria. 3. NVX is the only one with DTaP-IPV, and I would not expect to see the competition any time soon with a competitive product. By the time they catch up this will be DTaP-IPV-HiB. 4. It certainly adds a major endorsement to NVX's vaccine capabilities. Certainly the FDA has to like it. 5. It also says that we can expect CERTIVA + IPV to be coming soon in the US after the initial CERTIVA approval. NVX will dominate the "combination vaccine" market . Stock is up and the news has only hit Bloomberg so far.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next